AU2019288669B2 - Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods - Google Patents

Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods Download PDF

Info

Publication number
AU2019288669B2
AU2019288669B2 AU2019288669A AU2019288669A AU2019288669B2 AU 2019288669 B2 AU2019288669 B2 AU 2019288669B2 AU 2019288669 A AU2019288669 A AU 2019288669A AU 2019288669 A AU2019288669 A AU 2019288669A AU 2019288669 B2 AU2019288669 B2 AU 2019288669B2
Authority
AU
Australia
Prior art keywords
systems
methods
gene transfer
mediated gene
associated compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019288669A
Other languages
English (en)
Other versions
AU2019288669A1 (en
Inventor
Leah HOGDAL
Sandeep Kumar
David LARGAESPADA
Branden MORIARITY
Neil OTTO
Beau WEBBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R&d Systems Inc
Original Assignee
R&d Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R&d Systems Inc filed Critical R&d Systems Inc
Publication of AU2019288669A1 publication Critical patent/AU2019288669A1/en
Assigned to R&D SYSTEMS, INC. reassignment R&D SYSTEMS, INC. Request for Assignment Assignors: B-MOGEN BIOTECHNOLOGIES, INC.
Application granted granted Critical
Publication of AU2019288669B2 publication Critical patent/AU2019288669B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019288669A 2018-06-21 2019-06-21 Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods Active AU2019288669B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688278P 2018-06-21 2018-06-21
US62/688,278 2018-06-21
PCT/US2019/038410 WO2019246486A2 (en) 2018-06-21 2019-06-21 ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS

Publications (2)

Publication Number Publication Date
AU2019288669A1 AU2019288669A1 (en) 2021-01-21
AU2019288669B2 true AU2019288669B2 (en) 2025-06-26

Family

ID=67211911

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019288669A Active AU2019288669B2 (en) 2018-06-21 2019-06-21 Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods

Country Status (7)

Country Link
US (1) US11760983B2 (enExample)
EP (1) EP3810764A2 (enExample)
JP (2) JP2021527427A (enExample)
CN (1) CN112543808A (enExample)
AU (1) AU2019288669B2 (enExample)
CA (1) CA3104288A1 (enExample)
WO (1) WO2019246486A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3104288A1 (en) * 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
EP4161950A4 (en) * 2020-06-05 2024-06-26 B-Mogen Biotechnologies, Inc. Enhanced hat family member spin transposon-mediated gene transfer and associated compositions, systems, and methods
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2023004366A1 (en) 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Transposon-based modulation of gba1 and related compositions and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025054409A1 (en) * 2023-09-07 2025-03-13 Bio-Techne Corporation Mutant tcbuster transposase with improved solubility
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067644B2 (en) 2000-12-05 2006-06-27 Wisconsin Alumni Research Foundation Double transposition methods for manipulating nucleic acids
US7064246B2 (en) 2001-05-01 2006-06-20 Macrae Amy F Use of transposable elements for altering gene expression
US7262056B2 (en) 2001-11-08 2007-08-28 Mirus Bio Corporation Enhancing intermolecular integration of nucleic acids using integrator complexes
AU2002360986A1 (en) 2001-12-20 2003-07-09 Sungene Gmbh And Co. Kgaa Methods for the transformation of vegetal plastids
US20080008687A1 (en) 2003-02-10 2008-01-10 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Transposon-Based Targeting System
DK1594973T3 (da) 2003-02-10 2012-02-13 Max Delbrueck Centrum Transposonbaseret målretningssystem
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US20060252140A1 (en) * 2005-04-29 2006-11-09 Yant Stephen R Development of a transposon system for site-specific DNA integration in mammalian cells
EP2392657B1 (en) 2005-07-05 2013-09-25 The Chemo-Sero-Therapeutic Research Institute Modified transposon vector and its use
EP2160461B1 (en) 2007-07-04 2012-08-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Hyperactive variants of the transposase protein of the transposon system sleeping beauty
US8524979B2 (en) 2008-04-14 2013-09-03 National Taiwan University Termination of transgene expression via transposon-mediated break
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8399643B2 (en) 2009-02-26 2013-03-19 Transposagen Biopharmaceuticals, Inc. Nucleic acids encoding hyperactive PiggyBac transposases
ES2697535T3 (es) 2009-06-11 2019-01-24 Inter Univ Research Institute Corporation Research Organization Of Information And Systems Procedimiento para la producción de proteína
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130017978A1 (en) 2011-07-11 2013-01-17 Finnzymes Oy Methods and transposon nucleic acids for generating a dna library
CN103946952A (zh) 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
DK2825190T3 (en) 2012-03-15 2017-02-27 Cellectis REPEAT VARIABLE DIRESTS FOR TARGETING NUCLEOTIDES
PT2692865E (pt) 2012-07-30 2015-02-06 Nbe Therapeutics Llc Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
FI3536797T3 (fi) 2013-02-01 2023-03-23 Selexis Sa Siirtogeenin tehostettu ilmentäminen ja prosessointi
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2015234242B2 (en) 2014-03-21 2020-09-24 Children's Medical Research Institute Stable gene transfer to proliferating cells
CN103981204B (zh) 2014-03-24 2016-05-04 上海海洋大学 一种有活性的金鱼Tgf2转座子重组转座酶蛋白的表达方法
DK3129487T3 (da) 2014-04-09 2020-11-30 Dna Twopointo Inc Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
US20170107541A1 (en) 2014-06-17 2017-04-20 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
JP2017534295A (ja) 2014-09-29 2017-11-24 ザ ジャクソン ラボラトリー エレクトロポレーションによる遺伝子改変哺乳動物の高効率ハイスループット生成
EP3018200A1 (en) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
JP2018513681A (ja) 2015-03-31 2018-05-31 エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. 細胞または生物のゲノムへのＤＮＡ配列の標的化組み込みのためのＣａｓ９レトロウイルスインテグラーゼおよびＣａｓ９レコンビナーゼ系
CN107980059B (zh) 2015-04-13 2022-11-11 美克斯细胞有限公司 用于修饰基因组dna的方法和组合物
WO2016191618A1 (en) 2015-05-27 2016-12-01 Jianbiao Zheng Methods of inserting molecular barcodes
US11473082B2 (en) 2015-06-17 2022-10-18 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
WO2017046259A1 (en) 2015-09-16 2017-03-23 Ethris Gmbh Improved transposon system for gene delivery
ES3063691T3 (en) 2015-09-22 2026-04-20 Univ Wuerzburg J Maximilians A method for high level and stable gene transfer in lymphocytes
CN105154473B (zh) 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
EP4289944A3 (en) 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
KR102249982B1 (ko) 2015-12-14 2021-05-11 게놈프론티어 테라퓨틱스 인코포레이티드 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도
WO2017123758A1 (en) 2016-01-12 2017-07-20 Seqwell, Inc. Compositions and methods for sequencing nucleic acids
US20190048085A1 (en) 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy
CN109312361A (zh) 2016-02-26 2019-02-05 波赛伊达治疗学股份有限公司 转座子系统及应用方法
EP3219800A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
KR20190006952A (ko) 2016-03-31 2019-01-21 라이언 티씨알 피티이. 리미티드 외인성 바이러스-특이적 t 세포 수용체 (tcr)를 발현하는 비-활성화된 t 세포
EP3452082A1 (en) 2016-05-04 2019-03-13 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
CN107523547A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
CN107523548A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的t细胞及其用途
CN107523549A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达激活型抗体的car‑t细胞及其用途
CN107523545A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
KR20190031306A (ko) 2016-07-21 2019-03-25 맥스시티 인코포레이티드 게놈 dna를 변경하기 위한 방법 및 조성물
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018042776A1 (ja) 2016-08-30 2018-03-08 国立大学法人九州大学 Ｄｎａ結合タンパク質の結合領域の近傍に所望のｄｎａ断片を挿入する方法
WO2018057779A1 (en) 2016-09-23 2018-03-29 Jianbiao Zheng Compositions of synthetic transposons and methods of use thereof
CA3036926C (en) 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
JP7275043B2 (ja) 2016-12-16 2023-05-17 ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法
EP3568474A1 (en) 2017-01-10 2019-11-20 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
WO2018140644A1 (en) 2017-01-25 2018-08-02 Musc Foundation For Research Development Modified t cells and uses thereof
CA3104288A1 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Li, et al. A resurrected mammalian hAT transposable element and a closely related insect element are highly active in human cell culture. Proc Natl Acad Sci USA. Feb. 5, 2013; 110(6): E478-E487. *
NCBI, Genbank accession No. ABF20545.1 Dec. 31, 2007 *

Also Published As

Publication number Publication date
JP7733865B2 (ja) 2025-09-04
AU2019288669A1 (en) 2021-01-21
WO2019246486A2 (en) 2019-12-26
US11760983B2 (en) 2023-09-19
JP2021527427A (ja) 2021-10-14
JP2024041866A (ja) 2024-03-27
CN112543808A (zh) 2021-03-23
EP3810764A2 (en) 2021-04-28
CA3104288A1 (en) 2019-12-26
US20210277366A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
AU2019288669B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
IL267334A (en) Enhanced gene transfer mediated by the hat family transposon and related preparations, systems and methods
IL281159A (en) New CRISPR enzymes and systems
EP3873991A4 (en) FOAM COMPOSITIONS, FOAM MATRICES AND PROCESSES
EP3882345A4 (en) CRISPR-CAS12J ENZYME AND SYSTEM
CA3288624A1 (en) Game management system
EP3664816A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
EP3592674A4 (en) MODULAR TRANSFER UNITS, SYSTEMS AND PROCESSES
EP3365408A4 (en) Heat transfer compositions, methods and systems
IL281171A (en) Cellulose-synthase-like enzymes and their uses
EP3746519A4 (en) HEAT TRANSFER COMPOSITIONS, PROCEDURES AND SYSTEMS
GB2576614B (en) Compositions, uses and methods
EP3662416A4 (en) SYSTEMS AND PROCEDURES FOR STRINGING UNITS
ES3063731T3 (en) Heat transfer compositions, methods, and systems
EP3720281A4 (en) PESTICIDE COMPOSITIONS AND PROCEDURES
GB201804163D0 (en) Uses, compositions and methods
GB2591173B (en) Transfer line, GCMS arrangement and mounting assembly
EP3548287A4 (en) DIE ACTUATOR DEACTIVATION
EP3692110A4 (en) COMPOSITIONS, METHODS AND SYSTEMS FOR HEAT TRANSFER
EP3852530A4 (en) PESTICIDE COMPOSITIONS AND METHODS
HK40052607A (en) Oligonucleotide compositions and methods thereof
HK40051435A (en) Novel crispr enzymes and systems
AU2018902275A0 (en) suncycle hat
HK40040907A (en) Parenteral formulations and uses thereof
HK40020014A (en) Methods and compositions for gene transfer across the vasculature

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: R&D SYSTEMS, INC.

Free format text: FORMER APPLICANT(S): B-MOGEN BIOTECHNOLOGIES, INC.

FGA Letters patent sealed or granted (standard patent)